IN THE NEWS

Mayne Pharma Announces Strategic investment in US Facilities

ABOUT US

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma provides contract development and manufacturing services to more than 100 clients worldwide...

Read more

PRODUCTS

To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.

 

Read more

NEWS AND EVENTS

U.S. FDA APPROVES NEXTSTELLIS ®, NEW ORAL CONTRACEPTIVE FDA approval of novel oral contraceptive NEXTSTELLIS® New data on NEXTSTELLIS® presented at ISSWSH conference Mayne Pharma launches Microgestin® 24 Fe tablets in the United States Mayne Pharma successfully extends debt facility

Read more

PARTNERING

One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...

Read more

SPECIALTY TECHNOLOGIES

Mayne Pharma has a 30-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world...

Read more

FOR INVESTORS

Last Updated:

ASX:

1.05 AUD
Change: / Open:
Low: High:
Close: Volume:
Market Cap: 52 Week: -

Read more